奥翔药业: 奥翔药业第四届董事会第八次会议决议公告

Group 1 - The board of directors of Zhejiang Aoxiang Pharmaceutical Co., Ltd. held its eighth meeting of the fourth session on August 28, 2025, in a combined onsite and remote format [1][2] - The meeting was attended by 9 directors, and all resolutions were passed unanimously with 9 votes in favor, 0 against, and 0 abstentions [2] - The board approved the 2025 semi-annual report and its summary, the special report on the use of raised funds, the semi-annual evaluation report of the "Quality Improvement and Efficiency Enhancement" action plan, and the revision of the "Information Disclosure Delay and Exemption Management System" [2][3] Group 2 - The resolutions included the approval of the semi-annual report which had been reviewed by the audit committee [2] - The special report on the use of raised funds was also approved, with details available on the Shanghai Stock Exchange website and relevant financial newspapers [2] - The board's actions reflect a commitment to transparency and adherence to regulatory requirements [1][3]